key: cord-0694782-u5zmaroj
authors: Urbaniak‐Kujda, Donata; Biernat, Monika Maria; Skalec, Tomasz; Jacków‐Nowicka, Jagoda; Windyga, Jerzy; Wróbel, Tomasz
title: Successful treatment of COVID‐19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit
date: 2021-04-29
journal: Haemophilia
DOI: 10.1111/hae.14326
sha: 42fc3503ce2d47f90bebedc2f5032cec595f0dae
doc_id: 694782
cord_uid: u5zmaroj

nan

The course of infection with SARS-CoV-2 virus in patients with congenital bleeding disorders does not differ from the general population. COVID-19 in these patients can be mild but also can progress to severe pneumonia, respiratory failure and death. 1 The treatment of patients with COVID-19 and haemophilia A receiving emicizumab for bleeding prevention is particularly challenging because of the need to balance the increased risk of thrombotic events and bleeding, and reports in this population are scarce. 2 Emicizumab is a bispecific antibody that bridges factors X and IXa, which restores the function of missing factor VIII (FVIII) in haemophilia A. The recommended subcutaneous prophylactic dose is 3 mg/kg once weekly for the first 4 weeks, followed by a maintenance dose of usually 1.5 mg/ kg once weekly. At the usual recommended dose of emicizumab, the FVIII equivalent is about 10%-15%. Observations from registration studies have shown a small number of cases displaying increased risk of thrombotic events and thrombotic microangiopathy, especially when combined with bypassing agents (aPCC). 3 Thus, it could be thought that when an additional prothrombotic factor is present, as COVID-19, increased prothrombotic activity may occur. 2 On the other hand, patients on emicizumab prophylaxis may also experience bleeding episodes. The literature is less clear on how the drug may interact with thrombosis in the course of COVID-19. 4 We present a case of a 70-year-old male patient with severe haemophilia A on emicizumab prophylaxis that developed severe COVID-19. His haemophilia was diagnosed at age 5 with FVIII levels of 0.5% and complicated by an inhibitor at 50 years of age with maximum inhibitor titre up to 52 Bethesda units (BU). An inhibitor appeared as a consequence of intensive substitution treatment after right knee replacement surgery in 2000, and the patients underwent immune tolerance induction (ITI). After successful inhibitor eradication, the patient has received FVIII for secondary prophylaxis since 2013. In June 2017, the patient started emicizumab prophylaxis as a part of clinical trial, initially receiving a dose of 1.5 mg/kg weekly but because of recurrent bleeding episodes, the dose was increased to 3 mg/kg every week according to the protocol. Surgically, before starting emicizumab prophylaxis, the patient has undergone bilateral knee (1985, 2000) and hip replacements (1985, 2000) and sy- Evidence suggests that pulmonary thrombosis in situ may be one of the leading causes of death in COVID-19. 6 The pathophysiology of SARS-CoV-2 infection in patients with haemophilia is complex. 7 Haemophilia is characterized by a defect in thrombin production, resulting in reduced fibrin formation. For obvious reasons, in severe haemophilia A, marked elevation of factor VIII levels is not seen like that in patients without severe haemophilia. Therefore, it could be hypothesized that this might attenuate the potentiating effect of CAC in people with haemophilia A. However, many of the mecha- can support standard anticoagulant treatment without significant bleeding risk. 9 However, the use of thromboprophylaxis may be considered in combination with FVIII administration in severe cases and in precaution for invasive procedures. 8 Our patient had the following risk factors for severe COVID-19: age > 70 years, hypertension, history of numerous surgeries, immobilization, late hospitalization (advanced inflammatory changes in the lungs on admission) and intubation with subsequent tracheostomy. It is suggested that heparin's anti-inflammatory properties when used in patients with severe haemophilia A on emicizumab can prevent cytokine storm by acting as a protective agent against CAC. 9 As our patient's condition worsened, the dose of LMWH was increased, and additionally, pdFVIII was used under laboratory monitoring of FVIII plasma activity levels.

According to the recommendations, the FVIII trough level was maintained within 80 IU/dL, avoiding increases above 100 IU/dL. 8 

No funding was obtained for this study.

We thank native speakers of English from Ecorrector for the correction of the manuscript. The authors have received permission from the sponsor to publish the case report. no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results.

Informed consent was obtained from subject involved in the study.

Written informed consent has been obtained from the patient to publish this paper. Tomasz Wróbel 1

Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: Is inherited hypocoagulability overcoming acquired hypercoagulability of coronavirus disease

Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis

Emicizumab prophylaxis in hemophilia A with inhibitors

COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals

COVID-19 and its implications for thrombosis and anticoagulation

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Management of COVID-19 coagulopathy in patient with severe haemophilia A

Hermans C : interim guidance; coagulation products safety, supply and access (CPSSA) Committee of the World Federation of Hemophilia Management of COVID-19-associated coagulopathy in persons with haemophilia

Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra-atrial thrombosis in severe haemophilia with an inhibitor

COVID-19 (coronavirus disease 2019) pandemic caused by SARS-CoV-2: practical recommendations for people with hemophilia